Our results also showed higher expression of functionally active glycoproteins PSMA and Gal-3 in prostate cancer patients so, we next evaluated if targeting of PSMA and Gal-3 independently could serve as potential pharmacological treatment avenue. This evidence concerns the gene FOLH1 and prostate carcinoma.